
    
      This is a Phase 3, multicenter, open-label, treatment extension study evaluating the
      long-term safety and tolerability of eMG given once daily (QD) in participants who
      successfully participated in a double-blind lead-in study (MPUC3003 [NCT00744016 ] or
      MPUC3004 [NCT00767728 ]) or new participants who are currently in remission from symptoms of
      ulcerative colitis.
    
  